中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2010年
2期
79-82
,共4页
成虹%胡伏莲%张国新%施瑞华%杜奕奇%李兆申%韩炜%李延青%吴勤动%钱可大
成虹%鬍伏蓮%張國新%施瑞華%杜奕奇%李兆申%韓煒%李延青%吳勤動%錢可大
성홍%호복련%장국신%시서화%두혁기%리조신%한위%리연청%오근동%전가대
螺杆菌%幽门%氧氟沙星%随机对照试验
螺桿菌%幽門%氧氟沙星%隨機對照試驗
라간균%유문%양불사성%수궤대조시험
Helicobacter pylori%Ofloxacin%Randomized controlled trails
目的 观察含左氧氟沙星的三联疗法对幽门螺杆菌(Hp)根除效果及其患者依从性,比较传统的三联疗法与含左氧氟沙星的三联疗法对Hp的根除率.方法 为全国多中心随机平行对照临床研究,研究对象为既往未接受过根除治疗的Hp感染患者,将所有入选患者按照分层随机分为兰索拉唑+阿莫丙林+左氧氟沙星治疗组(LAL组)和兰索拉唑+阿莫西林+克拉霉素治疗组(LAC组),其中兰索拉唑30 mg 2次/d,阿莫西林1000 mg 2次/d,左氧氟沙星500 mg 1次/d,克拉霉素500mg 2次/d,均服药7 d.疗程结束4周后,采用尿素呼气试验判断根除效果,结果阴性者判断为Hp根除.共有300例Hp检测阳性的患者纳入研究,每组150例,平均年龄48.1岁,其中男153例;胃溃疡18例,十二指肠溃疡56例,慢性胃炎226例.结果 按符合方案(PP)分析Hp根除率,LAL组83.0%(122/147),LAC组78.2%(111/142),差异无统计学意义(P＞0.05);按意向治疗(ITT)分析,LAL组82.4%(122/148),LAC组74.5%(111/149),差异亦无统计学意义(P＞0.05).结论 含左氧氟沙星、阿莫西林的三联疗法作为一线根除Hp的治疗方案,可以获得较好的根除率,该方案患者依从性好,不良反应发牛率低,可以被推荐用于一线治疗Hp感染分案.
目的 觀察含左氧氟沙星的三聯療法對幽門螺桿菌(Hp)根除效果及其患者依從性,比較傳統的三聯療法與含左氧氟沙星的三聯療法對Hp的根除率.方法 為全國多中心隨機平行對照臨床研究,研究對象為既往未接受過根除治療的Hp感染患者,將所有入選患者按照分層隨機分為蘭索拉唑+阿莫丙林+左氧氟沙星治療組(LAL組)和蘭索拉唑+阿莫西林+剋拉黴素治療組(LAC組),其中蘭索拉唑30 mg 2次/d,阿莫西林1000 mg 2次/d,左氧氟沙星500 mg 1次/d,剋拉黴素500mg 2次/d,均服藥7 d.療程結束4週後,採用尿素呼氣試驗判斷根除效果,結果陰性者判斷為Hp根除.共有300例Hp檢測暘性的患者納入研究,每組150例,平均年齡48.1歲,其中男153例;胃潰瘍18例,十二指腸潰瘍56例,慢性胃炎226例.結果 按符閤方案(PP)分析Hp根除率,LAL組83.0%(122/147),LAC組78.2%(111/142),差異無統計學意義(P＞0.05);按意嚮治療(ITT)分析,LAL組82.4%(122/148),LAC組74.5%(111/149),差異亦無統計學意義(P＞0.05).結論 含左氧氟沙星、阿莫西林的三聯療法作為一線根除Hp的治療方案,可以穫得較好的根除率,該方案患者依從性好,不良反應髮牛率低,可以被推薦用于一線治療Hp感染分案.
목적 관찰함좌양불사성적삼련요법대유문라간균(Hp)근제효과급기환자의종성,비교전통적삼련요법여함좌양불사성적삼련요법대Hp적근제솔.방법 위전국다중심수궤평행대조림상연구,연구대상위기왕미접수과근제치료적Hp감염환자,장소유입선환자안조분층수궤분위란색랍서+아막병림+좌양불사성치료조(LAL조)화란색랍서+아막서림+극랍매소치료조(LAC조),기중란색랍서30 mg 2차/d,아막서림1000 mg 2차/d,좌양불사성500 mg 1차/d,극랍매소500mg 2차/d,균복약7 d.료정결속4주후,채용뇨소호기시험판단근제효과,결과음성자판단위Hp근제.공유300례Hp검측양성적환자납입연구,매조150례,평균년령48.1세,기중남153례;위궤양18례,십이지장궤양56례,만성위염226례.결과 안부합방안(PP)분석Hp근제솔,LAL조83.0%(122/147),LAC조78.2%(111/142),차이무통계학의의(P＞0.05);안의향치료(ITT)분석,LAL조82.4%(122/148),LAC조74.5%(111/149),차이역무통계학의의(P＞0.05).결론 함좌양불사성、아막서림적삼련요법작위일선근제Hp적치료방안,가이획득교호적근제솔,해방안환자의종성호,불량반응발우솔저,가이피추천용우일선치료Hp감염분안.
Objective To compare efficacy and tolerability of 7-day standard triple therapy versus 7-day levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori ( H. pylori) infection.Methods Three hundred consecutive H. pylori positive patients were randomized to receive: clarithromycin,amoxicillin, lansoprazole (Group A: n = 150) ; or amoxicillin, levofloxacin, lansoprazole (Group B: n =150). H. pylori status was rechecked by ~(13)C-urea breath test 4 weeks after the end of therapy. Results The eradication rates in intention to treat (ITT) and per protocol (PP) analyses were: Group A, 74. 5% ( 111/149) and 78. 2% (111/142) ; and Group B, 82.4% (122/148) and 83.0% (122/147). Although the eradication rate achieved with levofloxacin-based triple therapy was higher than that with standard therapies in either ITT or PP analysis, but no significantly difference was found between the two triple therapies. The incidence of side effects was similar among groups. Conclusions A 7-day levofloxacin-based triple therapy can achieve higher H. pylori eradication rate than standard regimen. The levofloxacin-based regimen can be one effective therapy for the first-line anti-H, pylori treatment.
